AtriCure, Inc. (ATRC)

Over the past six months, AtriCure's stock price increased by 14.73% between December 9, 2024, and December 8, 2025. In January 2026, shares reached a new 52-week high of $43.18. Preliminary financial results for Q4 and full year 2025 were announced on January 12, 2026, with projected revenue between $600 million and $610 million for 2026. In December 2025, the first patients were treated with the novel Dual Energy Platform. Third-quarter 2025 financial results showed worldwide revenue of $134.3 million, a 15.8% increase year-over-year. In October 2025, a Weiss Ratings report reaffirmed a "sell (d-)" rating. Insider selling activity has been observed in the past three months, with insiders selling $676,378.00 in company stock. Second-quarter 2025 worldwide revenue was $136.1 million, a 17.1% increase from Q2 2024. In February 2025, AtriCure reported a Q4 2024 loss of $0.08 per share, missing Zacks Consensus Estimates.

Specific information regarding the seasonality of demand for AtriCure's products and services is not readily available. The company's consistent growth in revenue across its franchises suggests a generally stable or increasing demand for its medical technologies.

AtriCure, Inc. is a medical device company focused on developing and providing innovative technologies for the treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, operating within the Health Technology sector and the Medical Equipment, Supplies & Distribution industry. The company develops and distributes medical devices utilized by electrophysiologists and cardiothoracic surgeons. Major products include the Isolator Synergy Ablation System, AtriClip Left Atrial Appendage Exclusion System, Hybrid AF Therapy, cryoICE Cryoablation System and cryoSPHERE probes, EPi-Sense Guided Coagulation System with VisiTrax Technology, LARIAT System, and Lumitip dissectors and Glidepath guides.

AtriCure, Inc. has a global presence, with operations in the United States, Europe (including Germany, France, the UK, and the Benelux region), Asia, Canada, and Australia. The company's corporate headquarters are located in Mason, Ohio, USA.

AtriCure generally holds a positive brand reputation among analysts, with a consensus rating of "Moderate Buy". The company's average rating score is 2.92, and it scored higher than 84% of companies evaluated by MarketBeat in the medical sector. A "sell (d-)" rating reaffirmed by Weiss Ratings in October 2025 indicates some dissenting views. Consistent product launches and strong revenue growth in key segments contribute positively to its reputation.

AtriCure, Inc. is primarily owned by institutional shareholders, who hold 96.82% of the company's stock, with major holders including Vanguard Group Inc, Wellington Management Group Llp and BlackRock, Inc.. Individual investors hold 3.61% of the shares. Insiders own 3.50% of the stock, and there has been net selling by insiders in the past three months. Discovery Group I LLC is noted as the largest individual shareholder.